# Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis

> **NCT03274895** · PHASE3 · COMPLETED · sponsor: **SIFI SpA** · enrollment: 135 (actual)

## Conditions studied

- Acanthamoeba Keratitis

## Interventions

- **DRUG:** PHMB 0.08%
- **DRUG:** Propamidine 0.1%
- **DRUG:** placebo
- **DRUG:** PHMB 0.02%

## Key facts

- **NCT ID:** NCT03274895
- **Lead sponsor:** SIFI SpA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-13
- **Primary completion:** 2021-06-30
- **Final completion:** 2022-03-30
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03274895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03274895, "Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03274895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*